Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The third and fourth largest, Pfizer and Eli Lilly, are also developing new drugs
A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes
When using GLP-1 medications, you might experience several benefits including a notable reduction in body weight, decreased appetite, improved blood sugar levels, and even some cardiovascular advantages such as a reduced risk of heart attack and stroke in certain individuals
Rybelsus is part of a comprehensive diabetes management plan that includes diet and exercise
Supplementation should be based on individual risk factors, symptoms and laboratory findings
The positive effects of GLP-1 medications extend beyond just diabetes control and weight loss
